Vaccine Treatment for Advanced Breast Cancer
A Phase I/II Study of an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Relapsed or Refractory Breast Cancer
Sponsor: NewLink Genetics Corporation
Terminated
Enrollment goals unable to be reached.
Other terminated trials from NewLink Genetics Corporation
- Non-small Cell Lung Cancer · Phase PHASE1 · Jan 2021
- Metastatic Melanoma · Phase PHASE2 · Jan 2021
- Pancreatic Cancer · Dec 2020
- Melanoma · Phase PHASE2 · Nov 2019
- Ovarian Cancer · Phase PHASE1/PHASE2 · Oct 2018
More terminations from NewLink Genetics Corporation
Other Breast Cancer trials with similar outcome
This PHASE1/PHASE2 trial investigates Breast Cancer and is currently terminated or withdrawn. NewLink Genetics Corporation leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jun 2020 [monthly]
Terminated PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Aug 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NewLink Genetics Corporation
For direct contact, visit the study record on ClinicalTrials.gov .